{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T06:35:09Z","timestamp":1786775709881,"version":"build-2736575974"},"reference-count":24,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T00:00:00Z","timestamp":1551830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Kaneka and Fresenius Medical Care"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Ther Apher Dial"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Taking into account the discordance between low\u2010density lipoprotein cholesterol (LDL\u2010C) and LDL particle (LDL\u2010P) number, cardiovascular risk more closely correlates with LDL\u2010P in patients. The aim of our study was to evaluate the number of lipid particles in patients with severe hypercholesterolemia treated with different lipid\u2010lowering regimens. Four groups of patients differing with respect to lipid\u2010lowering therapy were recruited from hypercholesterolemic outpatients and lipoprotein apheresis (LA) facilities, and were treated with statins alone (group A), with statins and proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors (PCSK9i) (group B), with statins and LA (group C), or with statins, PCSK9i, and LA (group D). Cholesterol, triglycerides, LDL\u2010C, high\u2010density lipoprotein cholesterol (HDL\u2010C), LDL\u2010P number and size, HDL\u2010P number and size were determined using nuclear magnetic resonance spectroscopy. The lowest LDL\u2010P number was achieved at the end of LA sessions in combination with statins or in combination with statins and a monoclonal PCSK9i (median; 25th and 75th percentile) (group C: 244\u2009nmoL\/L: 237, 244, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05; group D: 244\u2009nmoL\/L: 99, 307, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Comparing LDL\u2010P number at the start of LA (group C: 978\u2009nmoL\/L: 728, 1404; group D: 954\u2009nmoL\/L: 677, 1521) to the other patient groups (groups A and B), the lowest LDL\u2010P number was measured in patients treated with PCSK9i and a statin (group B): LDL\u2010P (762\u2009nmoL\/L: 604, 1043, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), large LDL\u2010P (472\u2009nmoL\/L: 296, 574, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05), and small LDL\u2010P (342\u2009nmoL\/L: 152, 494, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). Very low\u2010density lipoprotein and HDL particle sizes remained approximately the same in all groups. LA in combination with statins or in combination with statins and PCSK9i most reduced LDL\u2010P numbers in hypercholesterolemic patients.<\/jats:p>","DOI":"10.1111\/1744-9987.12792","type":"journal-article","created":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T05:43:38Z","timestamp":1548049418000},"page":"467-473","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["NMR\u2010based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9\u2010inhibitor therapy (NAPALI\u2010Study)"],"prefix":"10.1111","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6193-6377","authenticated-orcid":false,"given":"Volker JJ","family":"Schettler","sequence":"first","affiliation":[{"name":"Center for Nephrology GbR  G\u00f6ttingen Germany"},{"name":"BRAVE \u2013 Benefit for Research on Arterial Hypertension, Dyslipidemia and Vascular Risk and Education e.V.  G\u00f6ttingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Muellendorff","sequence":"additional","affiliation":[{"name":"Center for Nephrology GbR  G\u00f6ttingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Schettler","sequence":"additional","affiliation":[{"name":"BRAVE \u2013 Benefit for Research on Arterial Hypertension, Dyslipidemia and Vascular Risk and Education e.V.  G\u00f6ttingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Platzer","sequence":"additional","affiliation":[{"name":"MVZ Wagnerstibbe for Clinical Chemistry, Laboratory Medicine and Pathology  G\u00f6ttingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Norkauer","sequence":"additional","affiliation":[{"name":"numares AG  Regensburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Julius","sequence":"additional","affiliation":[{"name":"Lipidology and Extracorporeal Treatment and Apheresis Center, Department of Internal Medicine III University Hospital Carl Gustav Carus at the Technische Universit\u00e4t Dresden  Dresden Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claas\u2010Lennart","family":"Neumann","sequence":"additional","affiliation":[{"name":"Center for Nephrology GbR  G\u00f6ttingen Germany"},{"name":"BRAVE \u2013 Benefit for Research on Arterial Hypertension, Dyslipidemia and Vascular Risk and Education e.V.  G\u00f6ttingen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,6]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht273"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.19.2486"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000389"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000419"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw272"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx549"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.04.114"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.12.008"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002224"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.09.009"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2017.10.028"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.04.117"},{"key":"e_1_2_6_15_1","first-page":"171","article-title":"Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy","volume":"48","author":"Otvos JD","year":"2002","journal-title":"Clin Lab"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw106"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.06.871"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy319"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1159\/000443140"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2017.05.005"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2011.07.005"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2017.05.006"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11789-012-0043-9"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmg.2018.05.001"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2004.04.001"}],"container-title":["Therapeutic Apheresis and Dialysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1744-9987.12792","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.12792","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/1744-9987.12792","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1744-9987.12792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T15:22:15Z","timestamp":1694272935000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1744-9987.12792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,6]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1111\/1744-9987.12792"],"URL":"https:\/\/doi.org\/10.1111\/1744-9987.12792","archive":["Portico"],"relation":{},"ISSN":["1744-9979","1744-9987"],"issn-type":[{"value":"1744-9979","type":"print"},{"value":"1744-9987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,6]]},"assertion":[{"value":"2018-11-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}